Matthew Pauls

Chairman and CEO

Matthew Pauls was appointed Chairman and Chief Executive Officer (CEO) of Savara Pharmaceuticals in December 2020 after previously having served as Chairman and Interim CEO since September 2020. He has been a member of the company’s Board of Directors since April 2017. Additionally, Mr. Pauls is on the Board of Directors of Zyla Life Sciences (subsidiary) and Amplo Biotechnology, a private pre-clinical gene therapy company. With more than 25 years in the biopharmaceutical industry, Mr. Pauls brings a wealth of public company senior leadership and a successful track record as a general manager. Most recently he founded Spartan Biopharma, LLC where he provided strategic advisement to institutional investors, C-suite executives, and board directors. From 2014 through 2019, Mr. Pauls was President and Chief Executive Officer and on the Board of Directors of Strongbridge Biopharma plc (NASDAQ: SBBP), a rare disease biopharmaceutical company domiciled in Ireland, where he took the company public on the NASDAQ exchange in 2015. Mr. Pauls also previously served as Chairman of the Board of Directors at Mast Therapeutics. His earlier leadership positions include Chief Commercial Officer of Insmed, Inc. and Senior Vice President, Head of Global Commercial Operations at Shire Pharmaceuticals. He has also held senior management roles at Bristol-Myers Squibb and Johnson & Johnson and holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.

Dave Lowrance


Mr. Lowrance has served as Savara’s Chief Financial Officer since November 2016. From September 2014 to October 2016, Mr. Lowrance served as the Chief Financial Officer and Treasurer of Edgemont Pharmaceuticals, a fully-integrated specialty pharmaceutical company with multiple marketed products in the CNS space. From April 2011 to September 2014, Mr. Lowrance served as the Chief Financial Officer and Secretary of Acucela Inc., a clinical-stage biotechnology company that specializes in ophthalmic therapeutics, where he was responsible for overseeing all aspects of Acucela’s day-to-day operations, business development and growth endeavors, investor relations and corporate communications. While at Acucela, Mr. Lowrance helped lead a $162 million international IPO, with a listing on the Tokyo Stock Exchange. From March 2003 to April 2011, Mr. Lowrance was Vice President and Chief Financial Officer of Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company focused on commercializing branded prescription products, where he oversaw all aspects of finance and accounting, business and growth strategy and product development. Mr. Lowrance, a CPA, holds a B.B.A. in Accounting from the University of Georgia.

Badrul Chowdhury


Dr. Chowdhury joined Savara as Chief Medical Officer in November 2019. Previously he was at AstraZeneca where he held the position of Senior Vice President, Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late Stage Development in Biopharmaceuticals. For 16 years prior to that, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA) where he provided scientific and regulatory oversight of both common and rare diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, rheumatoid arthritis, systemic lupus erythromatosis, and various autoimmune and inflammatory diseases. Dr. Chowdhury is a medical doctor, and also holds a Ph.D. in Immunology. He completed Internal Medicine Residency training from the Wayne State University School of Medicine, Detroit, Michigan, and Fellowship training in Allergy and Immunology from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland. He is double board certified in Internal Medicine and Allergy and Immunology.

Anne Erickson

SVP, Chief of Staff

As Savara’s Chief of Staff, Ms. Erickson has line management responsibilities, an enterprise-wide focus on operational excellence, and leads the company’s global investor relations, corporate affairs, and advocacy efforts. She is a seasoned executive with many years of experience within the biotech and pharmaceutical sectors. Ms. Erickson has held leadership roles of increasing responsibility within corporate, consulting, and agency settings at companies like Mirati Therapeutics, Pfizer, and Ogilvy.

Cecilia Ganslandt

VP, Head of Clinical Development

Dr. Ganslandt (MD, MSc Pharmaceutical Medicine) serves as Head of Medical Affairs and has more than 19 years of experience from positions within global clinical development and medical affairs in small, mid-size and large pharma companies. She has supported a number of clinical development programs from early clinical phase up to and beyond marketing authorizations in Europe, US and Asia. Prior to joining Savara, she was CMO for Serendex Pharmaceuticals, assuming overall responsibility for nonclinical and clinical development.

Kate McCabe

SVP, Legal Affairs

Ms. McCabe serves as Savara’s SVP of Legal Affairs. Prior to joining Savara, Ms. McCabe practiced corporate and securities law at Wilson Sonsini Goodrich & Rosati, Professional Corporation, where she represented life sciences and technology companies in a variety of matters, including entity formation and structuring, venture capital financings, corporate governance, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. Ms. McCabe holds a B.S. in Accounting from Canisius College and a J.D. from the University of Texas School of Law.

Pernille Hemmingsen

VP, Head of Pharmaceutical Development

Dr. Hemmingsen serves as Vice President, Head of Pharmaceutical Development and has more than a decade of experience developing pharmaceutical products. With a background in biophysical chemistry and chemical engineering, she has successfully led the development of a diverse portfolio of products, and robust manufacturing methods, for therapies such as cancer targeting liposomes, antibody drug conjugates, tamper-resistant tablets, and enhanced formulations for diabetes. Pernille has held leadership roles within both small- and medium-size biotechs as well as large pharmaceutical companies such as Genmab and Novo Nordisk. Pernille holds a Ph.D. from the Department of Chemistry at the Technical University of Denmark and a Master of Business Administration from Copenhagen Business School.

Back to Top
Savara Nasdaq Opening Bell Ceremony - July 23, 2018

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.

We track anonymized user information to improve our website.
  • _ga
  • _gid
  • _gat

Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return. With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
  • __utma
  • __utmt
  • __utmb
  • __utmz
  • __utmv

Decline all Services
Accept all Services